Multiple myeloma: patients’ appeal denied

After two first positive judgments, a scientific study at the world’s largest blood cancer congress (“ASH”) in December 2017, appeals from the “Mieloma España” and “Myeloma Patients Europe” patients association and finally the refusal of medicines European Agency (EMA). At last some questions addressed to the European Parliament by Spanish exponents (Socialists and Democrats and EPP of the European People’s Party). The heart of the matter is a drug against multiple myeloma based on “plitidepsin”, produced by a Spanish company (at the moment the only therapies come from the United States and Japan). In the report on the preliminary authorization